Market Report, "Forecast Insight: Antibacterials", published -- Fast Market Research

May 16, 2011 - PRLog -- Introduction

Over the next decade, the fragmented antibacterials market will shift away from a blockbuster-business model, as generic erosion of market leaders and increased competition between new hospital drugs will trigger a decline in sales of branded antibacterials. While there is a lack of innovation with regards to new community drugs, the hospital sector will remain the only notable source of growth.

Features and benefits

* Analysis of the antibacterials market across the US, Japan, France, Italy, Germany, Spain and the UK.
* Detailed ten-year sales forecasts for marketed antibacterial drugs in each of the seven major markets.
* Thorough assessments of key marketed antibacterial brands.
* Snapshot of market dynamics in the Rest of World.

------------------------------------------------------------
Full Report Details at
- http://www.fastmr.com/prod/158677_forecast_insight_antibacterials.aspx
------------------------------------------------------------

Highlights

In 2009, antibacterial sales in the seven major markets totalled $19.6bn, declining at a compound annual growth rate (CAGR) of -1.6% since 2005. This decline was largely caused by generic erosion of market-leading community brands, such as Zithromax and Klacid, combined with a paucity of new product launches.
Over the next decade, genericization of key brands will drive a significant decline in market value, contributing to a loss of revenues from Levaquin/Cravit/Tavanic, Zosyn/Tazocin, and Zyvox alone of $3.2bn by 2019. Combined with growing resistance, this will cause increasing market fragmentation and reduce the potential for "blockbuster" sales.
The late-stage pipeline, much of which is targeting MRSA, will generate revenues totaling nearly $2.0bn by 2019. However, Datamonitor predicts that this upside will be insufficient to offset the decline caused by genericization, and total seven major market sales will fall from $19.6bn in 2009 to $16.4bn in 2019, with a CAGR of -1.8%.

Your key questions answered

* Assess and quantify the market opportunity for antibacterials, from generics to high-priced hospital brands.
* Understand the changing market dynamics of antibacterial drugs and success factors for leading brands.
* Assess the impact of key issues affecting the antibacterials market; generic erosion and growing levels of resistance.

Partial Table of Contents:

TABLE OF CONTENTS
Overview
Catalyst
Summary
About Datamonitor healthcare
About the Infectious Disease pharmaceutical analysis team
Executive Summary
Strategic scoping and focus
Datamonitor insight into the antibacterials market
Related reports
Upcoming related reports
CHAPTER 1 MARKET Definition and Overview
Market definition for this report
Countries and regions included in this report
Seven major market assessment
Class analysis
Brand analysis
Comparison with previous forecast
Rest of the World snapshot
CHAPTER 2 Brand Dynamics
Overview of competitive landscape
Levaquin/Cravit/Tavanic (levofloxacin; Johnson & Johnson/Daiichi Sankyo/Sanofi-Aventis)
Zosyn/Tazocin (piperacillin/tazobactam; Pfizer/Taisho Pharmaceutical)
Zyvox (linezolid; Pfizer)
Cubicin (daptomycin; Cubist Pharmaceuticals/Novartis/Merck & Co.)
Merrem/Meropen (meropenem; AstraZeneca/Dainippon Sumitomo)
Avelox/Octegra (moxifloxacin; Bayer/Merck & Co.)
Tygacil (tigecycline; Pfizer)
Vibativ (telavancin; Theravance/Astellas Pharma)
Zienam/Primaxin (imipenem/cilastatin; Merck & Co.)
Doribax/Finibax (doripenem; Johnson & Johnson/Shionogi & Co.)
Invanz (ertapenem; Merck & Co.)
Bibliography
Journal papers
Websites
Datamonitor reports
Appendix A - Market Assumptions
New product launches
Patent expiries
Data definitions, limitations and assumptions
Forecast methodology
Appendix B
Contributing experts
Conferences attended
Report methodology
About Datamonitor
Disclaimer

TABLE OF FIGURES
Figure 1: Antibacterial sales ($m) in the seven major markets, by type of product (marketed versus pipeline), 2005-19
Figure 2: Antibacterial sales ($m) and CAGR (%) in the seven major markets, by region, 2005-19
Figure 3: Antibacterial sales ($m) in the seven major markets, by country, 2005-19
Figure 4: Antibacterial sales ($m) in the seven major markets, by drug class, 2005-19
Figure 5: Sales of key antibacterial brands/molecules in the seven major markets ($m), 2009 and 2019
Figure 6: Comparison of fluoroquinolone class forecasts in the seven major markets, 2005-19
Figure 7: Comparison of antibacterial market forecasts in the seven major markets, 2005-19
Figure 8: Rest of the World versus seven major market sales split for the antibacterials market, 2009
Figure 9: Indexed annual sales of the antibacterials market in small and emerging markets, 2005-09
Figure 10: 2009 and updated sales forecast for Levaquin, Cravit, and Tavanic in the seven major markets ($m), 2009-19
Figure 11: 2009 and updated sales forecast for Zosyn and Tazocin in the seven major markets ($m), 2009-19
Figure 12: 2009 and updated sales forecast for Zyvox in the seven major markets ($m), 2009-19
Figure 13: 2009 and updated sales forecast for Cubicin in the seven major markets ($m), 2009-19
Figure 14: 2009 and updated sales forecast for Merrem and Meropen in the seven major markets ($m), 2009-19
Figure 15: 2009 and updated sales forecast for Avelox and Octegra in the seven major markets ($m), 2009-19
Figure 16: 2009 and updated sales forecast for Tygacil in the seven major markets ($m), 2009-19
Figure 17: 2009 and updated sales forecast for Vibativ in the seven major markets ($m), 2009-19

Full Table of Contents is available at:
-- http://www.fastmr.com/catalog/product.aspx?productid=1586...

About Datamonitor

The Datamonitor Group is a world-leading provider of premium global business information, delivering independent data, analysis and opinion across the Automotive, Consumer Markets, Energy & Utilities, Financial Services, Logistics & Express, Pharmaceutical & Healthcare, Retail, Technology and Telecoms industries. Datamonitor's market intelligence products and services ensure that you will achieve your desired commercial goals by giving you the insight you need to best respond to your competitive environment. View more research from Datamonitor at http://www.fastmr.com/catalog/publishers.aspx?pubid=1002

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

# # #

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

End